Compare · RMD vs VAPO
RMD vs VAPO
Side-by-side comparison of ResMed Inc. (RMD) and Vapotherm Inc. (VAPO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and VAPO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.13B, about 86.6x VAPO ($394.0M).
- RMD has hit the wire 9 times in the past 4 weeks while VAPO has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 2 for VAPO).
- Company
- ResMed Inc.
- Vapotherm Inc.
- Price
- $236.53+1.73%
- $1.25+21.95%
- Market cap
- $34.13B
- $394.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 2
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Vapotherm Inc.
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of intermittent and continuous aerosol nebulization by limiting condensate management; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is based in Exeter, New Hampshire.
Latest RMD
- 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
Latest VAPO
- SEC Form 15-12G filed by Vapotherm Inc.
- SEC Form EFFECT filed by Vapotherm Inc.
- SEC Form EFFECT filed by Vapotherm Inc.
- SEC Form EFFECT filed by Vapotherm Inc.
- Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.
- Director Arnerich Anthony L. returned $344,305 worth of shares to the company (232,993 units at $1.48), closing all direct ownership in the company (SEC Form 4)
- President and CEO Army Joseph returned $43,419 worth of shares to the company (452,698 units at $0.10), closing all direct ownership in the company (SEC Form 4)
- SVP & Chief Financial Officer Landry John returned $51,982 worth of shares to the company (71,661 units at $0.73), closing all direct ownership in the company (SEC Form 4)
- SVP & Chief Technology Officer Lawrence Brian returned $81,355 worth of shares to the company (60,188 units at $1.35), closing all direct ownership in the company (SEC Form 4)
- VP, Controller and CAO Mckay Dorota returned $36,506 worth of shares to the company (21,371 units at $1.71), closing all direct ownership in the company (SEC Form 4)